Biologics and risk of tuberculosis in autoimmune rheumatic diseases: A real-world clinical experience from India
International Journal of Rheumatic Diseases Feb 01, 2019
Shobha V, et al. - In this cross-sectional, observational, retrospective study conducted across 12 centers in Karnataka, India, authors assessed 195 candidates with an average age of 41 years to estimate the incidence of tuberculosis (TB) in relation to biologic used, screening test and TB prophylaxis. They noted 21 cases with latent TB positive and were given antitubercular prophylaxis, prior to biologics therapy. About 7 candidates belonging to the negative test group, developed TB during the follow-up. They recorded 96.52% and 96.25% of negative predictive values noted for Mantoux test and quantiFERON TB gold test, respectively. They noticed subjects on anti-tumor necrosis factor were more prone to develop TB. They suggested that a reduction in the risk of developing TB in individuals positive for screening could be possible with prophylaxis.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries